Skip to main content

Table 1 Patient demographics and pharmacokinetic parameters for neonates on gentamicin and amikacin

From: Plasma concentration and eGFR in preterm and term neonates receiving gentamicin or successive amikacin therapy

  

Gentamicin (n = 44)

Amikacin (n = 35)

Sex

Male

25 (56.8%)

23 (65.7%)

Female

19 (43.2%)

12 (34.3%)

Status

Preterm (< 37 weeks)

36 (81.8%)

24 (68.6%)

Term

8 (18.2%)

11 (31.4%)

Gestational age (weeks)

Median (range)

32 (27–40)

32 (24–40)

Postnatal age (days)

Median (range)

3 (1-14)

12 (5–25)

Postmenstrual age (days)

Median (range)

227 (190–285)

236 (179–293)

Birth weighta

Median (range), (g)

1573 (895–3920)

1920 (940–4500)

NBW (≥ 2500 g)

8 (18.2%)

9 (25.7%)

LBW (< 2500 g)

19 (43.2%)

14 (40.0%)

VLBW (< 1500 g)

15 (34.1)

10 (28.6%)

ELBW (1000 g)

2 (4.5%)

2 (5.7%)

Birth height (cm)

Median (range)

42 (30–53)

41 (28–55)

Body Surface Area (m2)

Median (range)

0.137 (0.088–0.240)

0.149 (0.088–0.267)

eGFR (mL/min/1.73 m2)

Median (range)

20.3 (8.7–50.4)

23.2 (10.7–64.9)

Dose (mg)

Median (range)

8.0 (4.5–17.0)

29 (14–62)

Peak concentration or Cmax (mcg/mL)

Median (range)

16 (4–64)

68 (11–260)

Half-life (h)

 

3.8 (1.4–28.0)

2.4 (0.8–9.5)

Drug clearance (L/h)

 

0.08 (0.01–1.39)

0.10 (0.01–1.76)

Time to reach toxicity threshold (gentamicin: 1 mcg/mL; amikacin: 5 mcg/mL) (h)

Median (range)

14.2 (4.3–118.0)

9.2 (1.1–42.0)

Duration of therapy (days)

Median (range)

5 (2–8)

7 (3–12)

  1. aNBW Normal body weight, LBW Low body weight, VLBW Very low body weight, ELBW Extremely low body weight